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Although little is known about etiology of childhood rhabdomyosarcoma (RMS), early life
factors are suspected in the etiology. We explored this hypothesis using linked data from
the California Cancer Registry and the California birth rolls. Incident cases were 359 children
<6-year-old (218 embryonal, 81 alveolar, 60 others) diagnosed in 1988–2008. Controls (205,
173), frequency matched on birth year (1986–2007), were randomly selected from the birth
rolls. We examined association of birth characteristics such as birth weight, size for gesta-
tional age, and timing of prenatal care with all-type RMS, embryonal, and alveolar subtypes.
Crude and adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) were esti-
mated using logistic regression. In contrast to a previous study, we observed statistically
non-significant association for embryonal subtype among high birth weight (4000–5250 g)
children for term births [OR (95% CI): 1.28 (0.85, 1.92)] and all births adjusted for gesta-
tional age [OR (95% CI): 1.21 (0.81, 1.81)]. On the other hand, statistically significant 1.7-fold
increased risk of alveolar subtype (95% CI: 1.02, 2.87) was observed among children with
late or no prenatal care and a 1.3-fold increased risk of all RMS subtypes among children of
fathers ≥35 years old at child birth (95% CI: 1.00, 1.75), independent of all covariates. Our
finding of positive association on male sex for all RMS types is consistent with previous
studies.While we did not find a convincingly positive association between high birth weight
and RMS, our findings on prenatal care supports the hypothesis that prenatal environment
modifies risk for childhood RMS.
Keywords: birth weight, prenatal care, pediatric, rhabdomyosarcoma
INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common type of soft-
tissue sarcoma among 0- to 19-year-olds, with the incidence rate
highest among children of ages 0–4 (1). Embryonal and alveolar
RMS are the two main histological subtypes, accounting for over
90 percent of cases in children under the age of five (2). Genetic
aberrations associated with RMS include germline mutations in
the TP53 tumor suppressor gene, translocation of chromosomes
2 and 13 or 1 and 13, and abnormalities on chromosome 11p15
where the IGF2 gene is located (3). Indeed, RMS is often charac-
terized by overexpression of the gene encoding insulin-like growth
factor 2 (IGF2). This can result from either loss of heterozygosity
(LOH, observed in both subtypes) due to the loss of the mater-
nal allele and duplication of paternal allele, or loss of imprinting
(LOI) via hypomethylation of the maternal IGF2 allele (observed
in embryonal RMS (4–7)). The alveolar subtype is further charac-
terized by translocations between chromosomes 2 or 1 and 13 (8).
In addition, germline mutations of the TP53 gene, also implicated
in regulation of IGF2 expression, are often associated with early
onset of RMS (9–11).
Childhood cancers tend to have a relatively short lag time
between exposure and disease onset (12). Therefore, early child-
hood disease such as RMS could be due to exposures during
prenatal, early infancy periods, or even during gametogenesis.
Although most RMS cases are sporadic in nature, suggesting de
novo genetic and epigenetic alterations perhaps due to environ-
mental factors, some cases (7–33%) have familial predisposition as
observed in families with Li-Fraumeni syndrome (LFS) and neu-
rofibromatosis (13, 14). Very little is known about environmental
factors that may trigger such genetic and epigenetic alterations
resulting in an increased susceptibility to these cancers in chil-
dren. A few studies have linked RMS in children with early life
factors such as parental preconceptional use of recreational drugs
including marijuana, maternal history of stillbirths, prenatal X-ray
exposure, higher maternal age at childbirth, parity, and high birth
weight (14–17). In two studies that examined embryonal RMS
separately from other subtypes, the latter four risk factors were of
more importance for the embryonal subtype (14, 17).
Overexpression of the gene encoding IGF2 due to LOI/LOH
observed in RMS has been implicated in both fetal overgrowth dis-
orders that predispose children to embryonal tumors (including
RMS) and RMS tumor cell growth and motility (6, 18, 19). Thus,
high birth weight, one of the manifestations of fetal overgrowth
disorder, could be an early marker of the genetic or epigenetic
abnormalities present in the IGF2 pathway that increase childhood
tumor susceptibility. Indeed, studies on Wilms tumor, another
embryonal tumor, have shown an association with high birth
weight (20). A recent study that examined childhood RMS cases
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using pooled data from five states, including 0- to 4-year-old cases
for 1988–1997 in California, provided some evidence of higher
RMS odds in larger birth weight and large size for gestational age
infants, particularly for embryonal RMS (14). However, the study’s
eligibility and matching criteria for case and control selection var-
ied across the states. This study improves on the previous work
by removing non-uniformity in sample selection, excluding con-
trols who died prior to diagnosis time of frequency matched cases,
and including 10 additional years of incident cases among 0- to
5-year-olds in California (diagnosed in 1988–2008). It first aims
to examine whether high birth weight as measured by birth weight
with and without adjustment for gestational age is predictive of
RMS, particularly embryonal RMS. In addition, it aims to examine
whether other factors reported on birth certificates may be related
to RMS risk in a large and ethnically diverse population.
MATERIALS AND METHODS
STUDY POPULATION
We conducted a population-based case-control study in California,
which included all cases diagnosed between 1988, since the incep-
tion of the California Cancer Registry (CCR), and 2008 among
children of ages 0–5 years. Using first name, last name, and date of
birth, we were able to match 89% of these cancer cases to a Califor-
nia birth certificate (1986–2007). Controls, frequency matched on
birth year, were randomly selected in 1:20 ratio for all California
registered<6-year-old cancer cases from the California birth roll.
We ensured that the controls were cancer free up to age six or at the
age attained by 2008 if younger than 6 years. Cancer-related infor-
mation including RMS diagnosis, histology, and year of diagnosis
were obtained from the CCR, while prenatal and perinatal data
including birth weight, gestational age, parental age, and demo-
graphic information were collected from birth registry records.
Institutional review board approvals were obtained from the Uni-
versity of California Los Angeles, the California Committee for the
Protection of Human Subjects, and the CCR.
The RMS cases were those assigned site group of IXa in the
International Classification of Childhood Cancer, third edition
(ICCC-3) and the subtypes were based on the following histo-
logical codes from the International Classification of Disease for
Oncology, third edition (ICD-O-3): 8900/3 – RMS (unspecified),
8901/3 – pleomorphic RMS, 8902/3 – mixed type RMS, 8910/3 –
embryonal RMS, 8912/3 – spindle cell RMS, 8920/3 – alveolar
RMS, and 8991/3 – embryonal sarcoma (21). Here, we evaluated
all histological types (“all-type RMS”) and embryonal and alveolar
subtypes separately.
We started with a total of 364 RMS cases and 209,700 con-
trols. After excluding 1,522 controls who died before age 6 years,
57 children with Down syndrome, and births with implausible or
extreme birth weight or gestational age values (27 with <500 g,
166 with >5250 g, 106 with gestational age <20 weeks, and 2654
with >45 weeks), the final study population included 359 RMS
cases and 205,173 controls.
DATA COLLECTION AND VARIABLE DEFINITIONS
The birth registry data included birth weight (grams), gestational
age (days), sex of infant, date of birth, parental age at child birth,
plurality (singleton, multiple birth), parity, maternal pregnancy
history (any prior pregnancy termination, any prior stillbirths),
prenatal care (present from the first trimester onward, started
after the first trimester/no care), and maternal race/ethnicity (non-
Hispanic white, Hispanic of any race, and others). Gestational age
was calculated based on the interval from date of last menstrual
period to birth. For children born in 2007, obstetric estimated ges-
tational age was also available. Thus, for those without gestational
age, the obstetric estimated gestational age was used where avail-
able. Size at gestation was assigned as small if birth weight was
less than the 10th percentile and as large if greater than the 90th
percentile of the birthweight standards for a given gestational age.
The 10th and the 90th percentile values were obtained for each
gestational week (20–45 weeks) by maternal race/ethnicity (non-
Hispanic white, Hispanic of any race, black, Asian/Pacific Islander,
and other) and child’s sex based on the total singleton live births in
California between 1988 and 2006 using the method described by
Alexander et al. (22). The large number of births in California dur-
ing the study period (n= 10,134,074) allowed us to use Californian
instead of US births as a standard; this standard is more likely to
be relevant for our diverse study population. In order to study the
role of socioeconomic status, we applied a census-based SES index
which combines seven census-block group indicators from 2000
census data: education index, median household income, percent
living 200% below poverty level, percent blue-collar workers, per-
cent older than 16 years in workforce without job, median rent,
and median housing value (23).
STATISTICAL ANALYSIS
We used logistic regression to examine, in crude and adjusted
models, associations between both birth weight and measures of
fetal growth at a given gestational age (term birth weight, birth
weight by gestational age, and size at gestational age) and the three
outcomes of interest (all-type RMS, embryonal RMS, and alveolar
RMS). In addition, we examined associations with the following
perinatal and demographic characteristics: parental age at child
birth, child’s sex, plurality, parity, timing of prenatal care, mater-
nal race/ethnicity, gestational age, and census-based SES. We also
conducted trend tests for birth weight,gestational age,and parental
age at child birth. The following covariates, selected based on lit-
erature, DAGs (directed acyclic graphs), and initial analysis, were
included in all adjusted models: birth year, child’s sex, plurality,
parity, maternal age, maternal race/ethnicity, and prenatal care.
The SES variable was excluded from the final analysis and the
results presented since the effect estimate of interest changed by
less than 1% when adding this variable in the model. All analyses
were carried out using SAS version 9.2 (SAS institute, Inc., NC,
USA).
RESULTS
Among the 359 RMS cases, the majority – 218 (61%) – were embry-
onal RMS cases, 81 (23%) alveolar, and 60 (17%) other types
or unspecified cases. Both case mothers and fathers were slightly
older than control parents. Male children were over-represented
among RMS cases overall (61%) as well as among embryonal and
alveolar subtypes (Table 1). A little over half of the cases had US-
born mothers (57%), while the rest were Mexican born (23%) and
other foreign born (19%) mothers (data not shown). A similar
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Table 1 | Frequency distribution of demographic and perinatal characteristics across cases and controls.
Variable name Embryonal (n=218) Alveolar (n=81) All-type RMS (n=359) Controls (n=205173)
Frequency (%) Frequency (%) Frequency (%) Frequency (%)
CHILD’S GENDER
Male 136 (62.4) 47 (58.0) 220 (61.3) 104677 (51.0)
Female 82 (37.6) 34 (42.0) 139 (38.7) 100496 (49.0)
PLURALITY
Singleton 209 (95.9) 77 (95.1) 345 (96.1) 200043 (97.5)
Multiple birth 9 (4.1) 4 (4.9) 14 (3.9) 5130 (2.5)
MATERNALAGEAT CHILD BIRTH
<20 19 (8.7) 8 (9.9) 29 (8.1) 22298 (10.9)
20–29 104 (47.7) 42 (51.9) 184 (51.3) 107054 (52.2)
30–34 60 (27.5) 19 (23.5) 92 (25.6) 47617 (23.2)
≥35 35 (16.1) 12 (14.8) 54 (15.0) 28169 (13.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 35 (0.0)
MATERNAL RACE/ETHNICITY
Non-Hispanic white 92 (42.2) 25 (30.9) 141 (39.3) 74182 (36.2)
Hispanic of any race 81 (37.2) 36 (44.4) 143 (39.8) 92200 (44.9)
Other (black, Asian/PI, other) 44 (20.2) 19 (23.5) 73 (20.3) 37589 (18.3)
Missing 1 (0.5) 1 (1.2) 2 (0.6) 1202 (0.6)
PATERNALAGEAT CHILD BIRTH
<20 5 (2.3) 4 (4.9) 10 (2.8) 7937 (3.9)
20–29 86 (39.5) 29 (35.8) 137 (38.2) 85838 (41.8)
30–34 52 (23.9) 20 (24.7) 89 (24.8) 49426 (24.1)
≥35 61 (28.0) 23 (28.4) 99 (27.6) 48633 (23.7)
Missing 14 (6.4) 5 (6.2) 24 (6.7) 13339 (6.5)
CENSUS-BASED SESa
1 (Lowest) 58 (26.6) 21 (25.9) 92 (25.6) 49005 (23.9)
2 42 (19.3) 18 (22.2) 70 (19.5) 47657 (23.2)
3 50 (22.9) 19 (23.5) 86 (24.0) 45984 (22.4)
4 26 (11.9) 10 (12.4) 48 (13.4) 33377 (16.3)
5 (Highest) 42 (19.3) 13 (16.1) 63 (17.6) 28513 (13.9)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 637 (0.3)
PREGNANCY HISTORY
Parity
Nulliparous 88 (40.4) 33 (40.7) 140 (39.0) 80776 (39.4)
One child 75 (34.4) 27 (33.3) 122 (34.0) 64082 (31.2)
Two children 33 (15.1) 11 (13.6) 57 (15.9) 34565 (16.9)
Three or more children 22 (10.1) 10 (12.4) 40 (11.1) 25750 (12.6)
PRE- AND POST-CONCEPTIONAL INFORMATION
Prenatal care
First trimester onward 173 (79.4) 59 (72.8) 277 (77.2) 162462 (79.2)
Started after first trimester/no care 45 (20.6) 22 (27.2) 79 (22.0) 40054 (19.5)
Missing 0 (0.0) 0 (0.0) 3 (0.8) 2657 (1.3)
Gestation length (weeks)
20–32 6 (2.8) 2 (2.5) 9 (2.5) 3655 (1.8)
33–36 16 (7.3) 4 (4.9) 27 (7.5) 16444 (8.0)
37–42 175 (80.3) 69 (85.2) 292 (81.3) 168524 (82.1)
43–45 13 (6.0) 3 (3.7) 17 (4.7) 8123 (4.0)
Missing 8 (3.7) 3 (3.7) 14 (3.9) 8427 (4.1)
Birth weight (in grams)
500–1499 2 (0.9) 1 (1.2) 3 (0.8) 1617 (0.8)
1500–2499 9 (4.1) 4 (4.9) 20 (5.6) 10367 (5.1)
(Continued)
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Table 1 | Continued
Variable name Embryonal (n=218) Alveolar (n=81) All-type RMS (n=359) Controls (n=205173)
Frequency (%) Frequency (%) Frequency (%) Frequency (%)
2500–3999 179 (82.1) 70 (86.4) 297 (82.7) 171111 (83.4)
4000–5250 28 (12.8) 6 (7.4) 39 (10.9) 22078 (10.8)
Size for gestational ageb
Small for gestational age (SGA) 23 (10.6) 9 (11.1) 40 (11.1) 20618 (10.1)
Normal size 164 (75.2) 64 (79.0) 273 (76.0) 156142 (76.1)
Large for gestational age (LGA) 23 (10.6) 5 (6.2) 32 (8.9) 19986 (9.7)
Missing 8 (3.7) 3 (3.7) 14 (3.9) 8427 (4.1)
aCreated using method described byYost et al. (23), which is based on seven census-block group indicators: education, median household income, % living <200%
poverty level, % blue-collar workers, %>16-year-olds in workforce without job, median rent, and median housing value. bStandard for race/ethnicity and sex generated
from the total births in California, 1988–2006.
distribution was observed for the control group as well. Mater-
nal history of pregnancy terminations and stillbirths were similar
across the control and case groups (data not shown). The remain-
ing demographic and perinatal characteristics also were similar
across the two groups (Table 1).
Our adjusted point estimates suggested a small statistically non-
significant increase in risk of embryonal RMS for high birth weight
(4000–5250 g) infants who were born at term and in all infants
when adjusting for gestational age [odds ratio (OR) (95% CI):
1.28 (0.85, 1.93) and 1.21 (0.81, 1.82) respectively], but not for
alveolar RMS or all-type RMS cases (Table 2). Trends toward
positive associations between embryonal RMS and high birth
weight was also observed for all the other measures of growth we
explored, i.e., large size for gestational age, birth weight without
adjustment for gestational age, a continuous per 500-g increase
in birth weight measure with and without adjustment for gesta-
tional age. However, all 95% CIs were wider and again included
the null value commensurate with no association (Table 2). The
Cochran–Armitage trend test for both birth weight and gestational
age showed no indication of linear association (2-sided p-values:
0.83 and 0.94 respectively).
In terms of other perinatal characteristics, we found statistically
significant increased risk for all-type RMS and embryonal RMS
among male compared to female children, and for alveolar RMS
among those with late initiated or no prenatal care [OR (95% CI):
1.52 (1.23, 1.89), 1.60 (1.22, 2.11), and 1.71 (1.02, 2.87) respec-
tively] after adjusting for all covariates. We found a very small
increase in risk for all-type RMS with each year increase in both
maternal and paternal age at childbirth [OR (95% CI): 1.02 (1.00,
1.04) and 1.02 (1.00, 1.04) respectively]. Examining categorical
variables, we observed a 32% increase in risk of all-type RMS for
children with 35 years or older fathers [OR (95% CI): 1.32 (1.00,
1.75)]. We also observed approximately 30% increase in risk in
mothers 30 years or older and fathers 35 years or older for embry-
onal RMS cases, albeit statistically non-significant (Table 3). The
Cochran–Armitage trend test for parental ages across the three
outcomes confirmed a linear trend of paternal age for all-type
RMS (2-sided p-value: 0.03), but not for embryonal and alveo-
lar subtypes separately (p-values: 0.09 and 0.36 respectively). As
for maternal age, none of the outcomes showed a linear trend
(p-values: 0.08 – all-type RMS, 0.06 – embryonal RMS, 0.72 –
alveolar RMS). In addition, our data suggest a possible 60% risk
increase for multiple compared to single births for all-type RMS
[OR (95% CI): 1.60 (0.94, 2.75)]. Furthermore, delivery at late
gestational ages (43–45 weeks) may increase embryonal RMS risk
by as much as 56% [OR (95% CI): 1.56 (0.89, 2.74)], but the 95%
CIs included the null values for these estimates indicating statis-
tically non-significant. In contrast, children of Hispanic mothers
appeared to have about a 20% reduced risk for embryonal [OR
(95% CI): 0.78 (0.57, 1.08)], but not for alveolar RMS [OR (95%
CI): 1.10 (0.64, 1.89)]. However, the 95% CI for adjusted models
included the null value (Table 3). We further compared the chil-
dren of Hispanic mothers born in Mexico and the US to US-born
white mothers separately by embryonal RMS status, and the esti-
mates for the two groups were similar [OR (95% CI): 0.75 (0.51,
1.09), 0.68 (0.43, 1.10), respectively].
DISCUSSION
We found a statistically non-significant association between high
birth weight and RMS, even though our models suggested small
(21–28%) risk increases, particularly for embryonal RMS, among
children in the 4000–5250 g birth weight group. Positive associa-
tions were suggested for birth weight with all of the measures we
employed and embryonal RMS. No associations were apparent for
alveolar RMS and our measures of fetal size at birth. While sta-
tistically non-significant, our point estimates for embryonal RMS
group are similar in direction to those reported by Ognjanovic et
al. (14), the study that has some sample overlap with our study
(about one-third). However, due to the smaller number of cases in
our study our estimates are less precise. Apart from birth weight,
we also assessed fetal growth as measured by term birth only, birth
weight adjusted for gestational age, and large for gestational age
to examine whether an increased fetal growth is more important
than the absolute birthweight reached. However, we were unable
to provide evidence for either measure being relevant.
The genetic aberrations observed among embryonal RMS and
alveolar RMS are associated with both genetic and epigenetic
changes resulting in overexpression of genes in the IGF2 pathway
(such as IGF2 and IGFR1). Accelerated fetal growth, often mea-
sured as high birth weight for gestational age, can be a marker of
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Table 2 | Unadjusted and adjusted logistic regression outcomes for birth weight and size at gestational age.
Variable name Unadjusteda Adjusted for covariatesb
Embryonal
(n=218)
Alveolar
(n=81)
All-type RMS
(n=359)
Embryonal
(n=218)
Alveolar
(n=81)
All-type RMS
(n=359)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
ALL BIRTHWEIGHT (IN GRAMS)
<2500 0.88 (0.48, 1.62) 1.00 (0.41, 2.49) 1.10 (0.72, 1.69) 0.75 (0.39, 1.44) 0.80 (0.30, 2.16) 1.00 (0.64, 1.58)
2500–3999 Reference
4000–5250 1.21 (0.81, 1.80) 0.68 (0.30, 1.57) 1.02 (0.73, 1.43) 1.16 (0.78, 1.74) 0.60 (0.24, 1.50) 0.96 (0.68, 1.36)
TERM BIRTHWEIGHT (IN GRAMS)
<2500 1.12 (0.46, 2.74) 1.08 (0.26, 4.40) 1.38 (0.71, 2.52) 0.92 (0.37, 2.33) 0.83 (0.19, 3.56) 1.13 (0.59, 2.19)
2500–3999 Reference
4000–5250 1.32 (0.88, 1.98) 0.58 (0.23, 1.45) 1.07 (0.76, 1.51) 1.28 (0.85, 1.93) 0.62 (0.25, 1.55) 1.05 (0.74, 1.48)
ALL BIRTHWEIGHTSADJUSTED FOR GESTATIONALAGE (IN GRAMS)
<2500 0.81 (0.40, 1.64) 1.22 (0.42, 3.49) 1.14 (0.70, 1.87) 0.69 (0.33, 1.44) 0.99 (0.33, 3.02) 1.04 (0.62, 1.75)
2500–3999 Reference
4000–5250 1.26 (0.84, 1.88) 0.58 (0.23, 1.43) 1.03 (0.74, 1.45) 1.21 (0.81, 1.82) 0.60 (0.24, 1.50) 1.00 (0.71, 1.40)
PER 500-GRAM INCREASE IN BIRTHWEIGHT FOR:
All births 1.03 (0.91, 1.16) 0.98 (0.81, 1.19) 1.01 (0.92, 1.11) 1.04 (0.91, 1.17) 0.99 (0.81, 1.22) 1.01 (0.91, 1.11)
Term birth (≥37 weeks) 1.06 (0.92, 1.23) 0.94 (0.74, 1.19) 1.04 (0.92, 1.16) 1.07 (0.92, 1.25) 0.98 (0.76, 1.26) 1.05 (0.93, 1.18)
Birth weight adjusted for gestational age 1.05 (0.92, 1.19) 0.91 (0.73, 1.14) 1.01 (0.91, 1.12) 1.05 (0.92, 1.20) 0.94 (0.75, 1.19) 1.00 (0.90, 1.12)
SIZE FOR GESTATIONALAGEc
Small for gestational age (SGA) 1.06 (0.69, 1.64) 1.07 (0.53, 2.14) 1.11 (0.80, 1.55) 1.01 (0.65, 1.58) 0.98 (0.48, 2.00) 1.07 (0.76, 1.50)
Normal size Reference
Large for gestational age (LGA) 1.10 (0.71, 1.69) 0.62 (0.25, 1.54) 0.92 (0.64, 1.32) 1.14 (0.73, 1.76) 0.51 (0.18, 1.40) 0.91 (0.62, 1.32)
aAdjusted for birthyear. bAdjusted for the following variables in addition to gestational age where mentioned: birth year, child sex, plurality, maternal race/ethnicity,
maternal age, parity, and prenatal care. cStandard for race/ethnicity and sex generated from the total births in California, 1988–2006.
such changes in DNA structure. However, many different factors
determine birth weight including parental build, race/ethnicity,
and diet. Therefore, the fetal growth measures based on birth
weight and gestational age are at best imprecise markers of over-
growth disorders linked to aberrations in the IGF2 pathway and
also implicated in RMS development. Thus, it is perhaps more
important to either determine a precise marker or to examine
factors that may trigger molecular changes of the genes in the
IGF2 pathway leading to increased susceptibility for childhood
RMS. Studies examining associations between environmental fac-
tors and epigenetic changes in IGF2 linked to various cancers are
lacking. So far, only a few studies examined associations between
preconceptional as well as pre- and early post-natal factors for
RMS. These studies reported positive associations for X-ray expo-
sure during pregnancy, parental preconceptional use of marijuana
and cocaine, maternal antibiotic use during pregnancy, organ meat
consumption by children, childhood infections, and childhood
exposure to chemicals (16, 17, 24). However, one study was very
small (33 cases and 99 controls, 24), and two reports were on the
same sample (322 cases and 322 controls matched on race, sex, and
age) and not only measured exposures retrospectively but required
mothers to recall exposures from 8 to 9 years prior to the interview
(16, 17).
Our findings on male sex and per year increase in parental
age at child’s birth for all RMS types are consistent with previous
studies (14, 24–26). In addition, our data showed a moderate (1.7-
fold) increase in risk for alveolar RMS among those with no or
late prenatal care and a 1.3-fold increase in risk for all-type RMS
among children with ≥35-year-old fathers at child birth, which
have not been reported before. Absence of early prenatal care is
often associated with mothers with lower SES status character-
ized by lower income, less education, being of certain racial/ethnic
groups, and with unintended pregnancies (27, 28). Furthermore, a
recent study of non-pregnant US women ages 15–44 reported that
both non-white and lower SES women are less likely to meet the
recommended daily intake of ≥400µg folic acid (29). Consistent
with these findings, we observed more mothers among the low-
est census-based SES group (24%), Hispanic and other non-white
mothers (25% and 19% respectively) reporting later/no prenatal
care compared to the highest SES group (10%), or non-Hispanic
white mothers (13%). This difference in report of later/no prena-
tal care across the two SES groups were higher among the cases
(32 vs. 13% in lowest vs. highest SES group) compared to controls
(24 vs.10% in lowest vs. highest SES group). Similarly, the differ-
ences in prenatal care across the two racial/ethnic groups were even
more notable among the alveolar RMS cases (36% among Hispanic
and 37% among other non-white mothers vs. 4% among white
mothers, respectively) compared to controls (25 vs. 13%) and the
embryonal RMS cases (21 vs. 17%). However, despite these varying
distributions in timing of prenatal care by SES and race/ethnicity,
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Table 3 | Unadjusted and adjusted logistic regression outcomes for perinatal characteristics.
Variable name Unadjusteda Adjusted for covariatesb
Embryonal
(n=218)
Alveolar
(n=81)
All-type RMS
(n=359)
Embryonal
(n=218)
Alveolar
(n=81)
All-type RMS
(n=359)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
CHILD’S CHARACTERISTICS
Child’s gender
Male 1.59 (1.21, 2.09) 1.33 (0.86, 2.07) 1.52 (1.23, 1.88) 1.60 (1.22, 2.11) 1.28 (0.82, 1.99) 1.52 (1.23, 1.89)
Female Reference
Plurality
Singleton Reference
Multiple birth 1.70 (0.87, 3.31) 1.93 (0.71, 5.28) 1.58 (0.92, 2.69) 1.70 (0.87, 3.32) 2.11 (0.76, 5.81) 1.60 (0.94, 2.75)
Gestation length (in weeks)
20–32 1.58 (0.70, 3.57) 1.34 (0.33, 5.46) 1.42 (0.73, 2.76) 1.45 (0.63, 3.34) 1.05 (0.25, 4.46) 1.30 (0.66, 2.55)
33–36 0.94 (0.56, 1.57) 0.59 (0.21, 1.61) 0.95 (0.64, 1.41) 0.89 (0.52, 1.50) 0.51 (0.18, 1.42) 0.89 (0.60, 1.34)
37–42 Reference
43–45 1.53 (0.87, 2.68) 0.97 (0.31, 3.09) 1.22 (0.75, 1.99) 1.56 (0.89, 2.74) 0.97 (0.30, 3.08) 1.23 (0.75, 2.01)
MATERNAL CHARACTERISTICS
Maternal age at child birth
<20 0.88 (0.54, 1.43) 0.92 (0.43, 1.96) 0.76 (0.51, 1.12) 0.85 (0.51, 1.41) 0.83 (0.38, 1.81) 0.73 (0.49, 1.10)
20-29 Reference
30-34 1.31 (0.95, 1.80) 0.99 (0.57, 1.69) 1.12 (0.87, 1.44) 1.33 (0.96, 1.84) 1.01 (0.57, 1.78) 1.13 (0.88, 1.47)
≥35 1.31 (0.89 (1.92) 1.00 (0.53, 1.91) 1.11 (0.82, 1.51) 1.30 (0.87, 1.95) 1.09 (0.56, 2.14) 1.10 (0.80, 1.51)
Per 1-year increase 1.02 (1.00, 1.05) 1.00 (0.97, 1.04) 1.02 (1.00, 1.04) 1.02 (1.00, 1.05) 1.01 (0.97, 1.05) 1.02 (1.00, 1.04)
Maternal race/ethnicity
Non-Hispanic white Reference
Hispanic of any race 0.72 (0.53, 0.97) 1.06 (0.63, 1.77) 0.81 (0.64, 1.02) 0.78 (0.57, 1.08) 1.10 (0.64, 1.89) 0.85 (0.66, 1.08)
Other 0.95 (0.66, 1.37) 1.41 (0.78, 2.57) 1.02 (0.76, 1.35) 0.98 (0.68, 1.41) 1.44 (0.79, 2.64) 1.02 (0.77, 1.36)
PREGNANCY HISTORY
Parity
Nulliparous Reference
One child 1.08 (0.79, 1.47) 1.02 (0.62, 1.70) 1.10 (0.86, 1.40) 1.01 (0.73, 1.38) 1.01 (0.60, 1.71) 1.03 (0.80, 1.33)
Two children 0.88 (0.59, 1.31) 0.77 (0.39, 1.52) 0.95 (0.70, 1.29) 0.82 (0.54, 1.24) 0.67 (0.32, 1.39) 0.87 (0.63, 1.21)
Three or more children 0.78 (0.49, 1.25) 0.95 (0.47, 1.94) 0.90 (0.63, 1.27) 0.70 (0.43, 1.16) 0.84 (0.39, 1.80) 0.82 (0.56, 1.19)
Prenatal care began in
First trimester Reference
After first trimester/no care 1.01 (0.72, 1.41) 1.62 (0.98, 2.67) 1.17 (0.91, 1.50) 1.17 (0.83, 1.65) 1.71 (1.02, 2.87) 1.30 (1.00, 1.68)
PATERNAL CHARACTERISTICS
Paternal age at child birth
<20 0.63 (0.26, 1.55) 1.49 (0.52, 4.24) 0.79 (0.42, 1.50) 0.67 (0.27, 1.67) 1.45 (0.50, 4.23) 0.82 (0.43, 1.58)
20–29 Reference
30–34 1.06 (0.75, 1.49) 1.17 (0.66, 2.06) 1.13 (0.86, 1.47) 1.08 (0.75, 1.55) 1.26 (0.69, 2.31) 1.16 (0.88, 1.54)
≥35 1.28 (0.92, 1.77) 1.31 (0.76, 2.27) 1.27 (0.98, 1.65) 1.31 (0.92, 1.87) 1.45 (0.80, 2.63) 1.32 (1.00, 1.75)
Per 1-year increase 1.02 (1.00, 1.04) 1.02 (0.99, 1.05) 1.02 (1.00, 1.03) 1.02 (1.00, 1.04) 1.02 (0.99, 1.06) 1.02 (1.00, 1.04)
aAdjusted for birthyear. bAdjusted for the following variables: birth year, child sex, plurality, maternal race/ethnicity, maternal age, parity, and prenatal care. Prenatal
care not included in the model for child’s sex.
we did not observe significant interactions between prenatal care
and SES (p= 0.15) or maternal race/ethnicity (p= 0.15). The pos-
itive association we observed with alveolar RMS remained even in
the model adjusted for both maternal race/ethnicity and SES [OR
(95% CI): 1.70 (1.02, 2.83)]. Lack of early prenatal care may be
associated with lack of important nutrients in the maternal diet,
exposure to harmful agents, or risky lifestyle factors, all of which
should be explored in future studies.
We conducted a population-based case-control study with con-
trols selected at random from all California born children. Thus,
our study is less likely to have been affected by bias in control selec-
tion. Furthermore, we were able to link our data to death records
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and exclude controls who died prior to the diagnosis of the fre-
quency matched cases, reducing potential inaccuracy in estimates.
RMS is a rare disease, but our data for a 20-year period made it
possible not only to use a uniform case/control ascertainment and
examine various risk factors for RMS, but also to distinguish the
two most common histological subtypes. Embryonal and alveolar
RMS have distinct genetic characterizations, age- and sex-specific
distributions, and different prognoses (1, 2). Thus, it is likely that
different factors play an etiologic role for these subtypes, which
was supported by the differences we observed across the two sub-
types for risk factors of interest such as fetal growth measures,
prenatal care, and maternal race/ethnicity.
Our study was limited by multiple comparisons and potential
measurement errors associated with birth certificate data. While
the use of California birth certificates for all risk factors allowed
us to avoid recall bias and provided fairly complete data, we were
limited in terms of the types of data available to assess accelerated
fetal growth. We used large/small for gestational age, term birth
weight, and birth weight adjusted for gestational age as measures of
accelerated fetal growth whereas fundal height or repeated ultra-
sound may be more accurate measures, which were not available
to us. Furthermore, data quality may not be equal for all vari-
ables of interest. For example, slightly more birth records missed
or had implausible values for gestational age data (4%) compared
to most other variables including birth weight, which may intro-
duce selection bias if the missing data are non-random. Higher
proportions of missing or inaccurate gestational age data on birth
records have been reported for women of lower SES status, receiv-
ing later prenatal care, and non-white mothers (30, 31). In our
data, we found this to be true of missing data for census-based
SES and maternal race/ethnicity, but not for prenatal care, and
there was no difference in missing data by case status. Studies
on reliability and validity of birth certificate data have indicated
high reliability and validity for information on demographics,
birth weight, delivery method, and source of prenatal care pay-
ment and low to moderate for gestational age and prenatal care
data (32–34). The gestational age information we used was esti-
mated based on date of last menstrual period. This method is
also subject to inaccuracies for mothers who have an irregular
menstrual cycle, bleeding in early pregnancy, or preconceptional
amenorrhea (35, 36), and may introduce additional errors in fetal
growth measurements.
In summary, our study provides some additional evidence in
support of a weak association between accelerated fetal growth and
childhood RMS. Furthermore, the estimated effect size reflects
those from earlier reports for the embryonal subtype. However,
sample size limitations preclude us from drawing conclusions
except that the effect seems to be relatively weak. Given the sam-
ple size for the embryonal subtype and controls in this study,
the smallest effect size the study can detect at 80% power is an
OR of 1.40. Our findings on starting time of prenatal care and
parental age at childbirth further support the notion that the early
fetal/embryonic environment may be important for developing
RMS in early childhood. However, further study with better mea-
sures of prenatal care is needed to explore and confirm this associ-
ation. Given that the majority of RMS cases are sporadic in nature,
environmental factors may play an important role in the genomic
and epigenetic alterations causing these tumors. For example, diet
and supplement intake during pregnancy may cause molecular
alterations observed in RMS cases. Future studies should incor-
porate additional, accurate measures of early life and pregnancy
exposures associated with birth weight or have more accurate fetal
growth measure such as fundal height and additional predictors of
birth weight (e.g., parental height and weight, pregnancy weight
gain, diet/supplements) to improve our understanding of RMS
etiology.
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